117 related articles for article (PubMed ID: 3931433)
1. A monoclonal antibody with selectivity for human kappa myeloma and lymphoma cells which has potential as a therapeutic agent.
Walker KZ; Boux HA; Hayden GE; Goodnow CC; Raison RL
Adv Exp Med Biol; 1985; 186():833-41. PubMed ID: 3931433
[TBL] [Abstract][Full Text] [Related]
2. The surface expression of a tumor-associated antigen on human kappa myeloma cells.
Boux HA; Raison RL; Walker KZ; Musgrove E; Basten A
Eur J Immunol; 1984 Mar; 14(3):216-22. PubMed ID: 6423392
[TBL] [Abstract][Full Text] [Related]
3. MDX-1097 induces antibody-dependent cellular cytotoxicity against kappa multiple myeloma cells and its activity is augmented by lenalidomide.
Asvadi P; Cuddihy A; Dunn RD; Jiang V; Wong MX; Jones DR; Khong T; Spencer A
Br J Haematol; 2015 May; 169(3):333-43. PubMed ID: 25653020
[TBL] [Abstract][Full Text] [Related]
4. A tumor-associated antigen specific for human kappa myeloma cells.
Boux HA; Raison RL; Walker KZ; Hayden GE; Basten A
J Exp Med; 1983 Nov; 158(5):1769-74. PubMed ID: 6195295
[TBL] [Abstract][Full Text] [Related]
5. A rat model system for radioimmunodetection of kappa myeloma antigen on malignant B cells.
Walker KZ; Seymour-Munn K; Keech FK; Axiak SM; Bautovich GJ; Morris JG; Basten A
Eur J Nucl Med; 1986; 12(9):461-7. PubMed ID: 3102238
[TBL] [Abstract][Full Text] [Related]
6. Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies.
Meeker T; Lowder J; Cleary ML; Stewart S; Warnke R; Sklar J; Levy R
N Engl J Med; 1985 Jun; 312(26):1658-65. PubMed ID: 3923352
[TBL] [Abstract][Full Text] [Related]
7. Chimeric Anti-Human Podoplanin Antibody NZ-12 of Lambda Light Chain Exerts Higher Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity Compared with NZ-8 of Kappa Light Chain.
Kaneko MK; Abe S; Ogasawara S; Fujii Y; Yamada S; Murata T; Uchida H; Tahara H; Nishioka Y; Kato Y
Monoclon Antib Immunodiagn Immunother; 2017 Feb; 36(1):25-29. PubMed ID: 28157429
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal antibody studies in B(non-T)-cell malignancies.
Shimoyama M; Minato K; Tobinai K; Nagai M; Hirose M
Jpn J Clin Oncol; 1983 Sep; 13(3):477-88. PubMed ID: 6417373
[TBL] [Abstract][Full Text] [Related]
9. Novel immunization protocol and ELISA screening methods used to obtain and characterize monoclonal antibodies specific for human light chain variable-region subgroups.
Abe M; Goto T; Wolfenbarger D; Weiss DT; Solomon A
Hybridoma; 1993 Aug; 12(4):475-83. PubMed ID: 8244419
[TBL] [Abstract][Full Text] [Related]
10. Spontaneous alteration of idiotype in a monoclonal B-cell lymphoma. Escape from detection by anti-idiotype.
Raffeld M; Neckers L; Longo DL; Cossman J
N Engl J Med; 1985 Jun; 312(26):1653-8. PubMed ID: 3923351
[TBL] [Abstract][Full Text] [Related]
11. Studies on monoclonal anti-isotypic and anti-idiotypic antibodies against leukemia and myeloma: I. Study on monoclonal anti-idiotypic antibodies against lambda chain protein of myeloma.
Wang XL; Zhu HF; Zhang Y; Su N; Shen GX; Tang JZ; Zhang JL; Sun HY
J Tongji Med Univ; 1990; 10(3):169-75. PubMed ID: 2123943
[TBL] [Abstract][Full Text] [Related]
12. [The analysis of immunoregulation of idiotype synthesis by monoclonal anti-idiotypic antibody].
Fujisaku A
Hokkaido Igaku Zasshi; 1986 Jan; 61(1):134-45. PubMed ID: 3084367
[TBL] [Abstract][Full Text] [Related]
13. Immunoperoxidase staining of bone marrow sections.
Hitzman JL; Li CY; Kyle RA
Cancer; 1981 Dec; 48(11):2438-46. PubMed ID: 6794902
[TBL] [Abstract][Full Text] [Related]
14. Characterization of a monoclonal antibody having selective reactivity with normal and neoplastic plasma cells.
Tong AW; Lee JC; Stone MJ
Blood; 1987 Jan; 69(1):238-45. PubMed ID: 3098320
[TBL] [Abstract][Full Text] [Related]
15. Immunocytochemical detection of kappa and lambda light chain V region subgroups in human B-cell malignancies.
Solomon A; Weiss DT; Macy SD; Antonucci RA
Am J Pathol; 1990 Oct; 137(4):855-62. PubMed ID: 2121042
[TBL] [Abstract][Full Text] [Related]
16. Acquired C1-inhibitor deficiency associated with antiidiotypic antibody to monoclonal immunoglobulins.
Geha RS; Quinti I; Austen KF; Cicardi M; Sheffer A; Rosen FS
N Engl J Med; 1985 Feb; 312(9):534-40. PubMed ID: 3918266
[TBL] [Abstract][Full Text] [Related]
17. B-cell malignancy and monoclonal gammopathy, and idiotype of cell surface and serum immunoglobulin.
Sugai S; Takiguchi T; Hirose Y; Konaka Y; Shimizu S; Konda S
Jpn J Clin Oncol; 1983 Sep; 13(3):533-42. PubMed ID: 6417376
[TBL] [Abstract][Full Text] [Related]
18. Derivatives of anti-idiotype antibodies in the treatment of B-cell lymphoma.
Glennie MJ; Stevenson GT
Adv Exp Med Biol; 1985; 186():843-53. PubMed ID: 3876727
[No Abstract] [Full Text] [Related]
19. Surface immunoglobulin in immunoproliferative diseases.
Teodorescu M; Mayer EP
Ann Clin Lab Sci; 1978; 8(5):353-65. PubMed ID: 101125
[TBL] [Abstract][Full Text] [Related]
20. Two monoclonal antibodies (OKIa1 and OKT10) for the study of the final B cell maturation.
Van Camp B; Thielemans C; Dehou MF; De Mey J; De Waele M
J Clin Immunol; 1982 Jul; 2(3 Suppl):67S-74S. PubMed ID: 6813349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
